Topic: Health

A drug already in trials to treat hepatitis C may also work against hepatitis E. This could be a game-changer for the millions of people worldwide who are infected with this virus each year.

Hepatitis E is a serious disease that infects millions of people globally and causes around 70,000 deaths annually. Despite its impact, there is currently no approved vaccine or targeted treatment available. However, researchers may soon have a breakthrough in the form of bemnifosbuvir, a compound that shows strong activity against hepatitis E viruses (HEV). This drug was identified by an international team of scientists from Germany and China while screening a collection of antiviral compounds.

Bemnifosbuvir belongs to a class of molecules known as nucleotide/nucleoside analogues. Because it is already being tested in clinical trials for hepatitis C, scientists are hopeful that it could be repurposed more quickly as a treatment for hepatitis E. The researchers published their findings in the journal Gut on March 6, 2026.

The team began by analyzing a commercially available library of nucleotide/nucleoside analogues and tested around 500 compounds using a specially engineered hepatitis E virus that produces a fluorescent signal. They infected cell cultures with this modified virus and then treated the cells with different compounds. By tracking the fluorescence, they could quickly determine whether the virus continued to replicate.

The results showed that bemnifosbuvir was able to stop the virus from reproducing while keeping the treated cells healthy. Follow-up studies in animals confirmed that the drug reduced both viral activity and liver inflammation.

If the ongoing clinical trials of bemnifosbuvir against hepatitis C are successful, the drug could soon also be available for off-label use against hepatitis E.

Why It Matters

This breakthrough has the potential to improve the lives of millions of people worldwide who are infected with hepatitis E each year. It's a reminder that even in the face of complex scientific challenges, innovative research can lead to life-changing discoveries.

Key Facts

• Hepatitis E infects millions of people globally and causes around 70,000 deaths annually.
• Bemnifosbuvir is a compound that shows strong activity against hepatitis E viruses (HEV).
• The drug was identified by an international team of scientists from Germany and China while screening a collection of antiviral compounds.
• Bemnifosbuvir belongs to a class of molecules known as nucleotide/nucleoside analogues.
• The drug is already being tested in clinical trials for hepatitis C, which could speed up its development as a treatment for hepatitis E.

Key Terms

Hepatitis E

A serious viral infection that can cause liver disease and death.

Implications

This breakthrough has the potential to improve the lives of millions of people worldwide who are infected with hepatitis E each year. It's a reminder that even in the face of complex scientific challenges, innovative research can lead to life-changing discoveries.